KDx Diagnostics inc. is announcing the partnership with leading distributors in the Middle East & Europe serves as a testament to KDx Diagnostics’ dedication to expanding its global presence.
|
[15-November-2023] |
LOS GATOS, Calif., Nov. 15, 2023 /PRNewswire/ -- KDx Diagnostics inc. is announcing the partnership with leading distributors in the Middle East & Europe serves as a testament to KDx Diagnostics' dedication to expanding its global presence. The URO17® Bladder Cancer Test has already made significant strides in improving the diagnostic process for bladder cancer in the United States, and now, we are excited to extend our reach to patients and healthcare providers across Europe and the Middle East. The URO17Ò test, known for its exceptional sensitivity and specificity, has been in clinical use as a CE-IVD test outside the United States. With these new collaborations, KDx is strengthening its presence across Europe, ensuring that healthcare providers and patients have easy access to this groundbreaking diagnostic tool. Our newly recognized distribution partners include: Gulf Pharmacy, Serving the needs of healthcare professionals in MENA region. Clinomics, Covering Hungry and other European countries in the region. "We are delighted to partner with Gulf Pharmacy and Clinomics. These key players bring a wealth of experience and a deep understanding of the medical device industry, which will further enhance our ability to serve clinicians with easier access to the URO17Ò CE-IVD test, ultimately benefiting patients by enabling earlier detection and timely intervention for bladder cancer," said Sholeh Jahanfard, President and COO at KDx Inc. About KDx Diagnostics Inc. Contact: Gulf Pharmacy Clinomics Europe Ltd. URO17 is a registered trademark of KDx.
SOURCE KDx Diagnostics Inc. |